AstraZeneca Awaits "Orange Book" Listing For Three Prilosec Patents
Executive Summary
AstraZeneca has submitted to FDA three additional patents covering its proton pump inhibitor Prilosec for listing in the "Orange Book."
You may also be interested in...
AstraZeneca Loses One Prilosec Patent: Three Others To Be Decided By Aug.
A decision on the relevance of AstraZeneca's antibiotic-related patents for the proton pump inhibitor Prilosec (omeprazole) is expected by August.
AstraZeneca Loses One Prilosec Patent: Three Others To Be Decided By Aug.
A decision on the relevance of AstraZeneca's antibiotic-related patents for the proton pump inhibitor Prilosec (omeprazole) is expected by August.
Andrx To Launch Lovastatin XL In 2002 With 150-Rep Sales Force
Andrx plans to launch extended-release lovastatin in 2002 for hyperlipidemia with three years of exclusivity, President Elliot Hahn, PhD, announced March 28 at the Banc of America Securities Healthcare Conference in Las Vegas.